2nd Antigen-Specific Immune Tolerance Drug Development Summit

2nd Antigen-Specific Immune Tolerance Drug Development Summit is organized by Hanson Wade and will be held from Mar 26 - 28, 2019 at Wyndham Boston Beacon Hill, Boston, Massachusetts, United States of America.

Course Description:
As the race to generate compelling clinical data to prove the concept of antigen-specific immunotherapies gains momentum, the 2nd Antigen-Specific Immune Tolerance Drug Development Summit returns to Boston in 2019 to help large pharma, biotech, and academic researchers to overcome the complexity of auto-immune mediated disorders, expand opportunities through combination strategies and undertake a more precise and antigen-specific approach to novel drug development.

KEY Features of the 2nd Antigen-Specific Immune Tolerance Drug Development Summit:
• World-Class Speaker Faculty from the Likes of GSK, Eli Lilly, ITN and FDA
• Curated Learning Journey from Early Discovery to Clinical Development
• An Impactful 3-Day Summit with Solution Led Case Studies from the Fields of Allergy and Autoimmunity
• Deep-Dive into the Crucial Challenges and Critical Decision Making to Successfully Translate Promising Strategies into Effective Therapies
• Critical Strategic Discussions Focused On Expanding Opportunities Through Combination Therapies to Address Unmet Clinical Needs
• Intimate Networking with Key Decision-Makers from large Pharma, Biotech and Academia Through High-Quality Discussions

Time: 8:00 am - 5:00 pm

Pre-Conference Workshop Day - Mar 26, 2019

 Additional details will be posted as soon as they are available.